利它素相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	不含卤素的聚合物和利用它的汽车电线	CN200480035822.8	2004-02-27	CN100509939C	2009-07-08	金吾荣; 尹承勋; 林和俊
本发明公开一种用于不含卤素的汽车电缆的绝缘组合物，该绝缘组合物包含基质树脂，以及按100重量份的该基质树脂计为50～200重量份的金属氢氧化物阻燃剂和0.5～20重量份的抗氧剂，其中所述基质树脂由1～80重量份的聚乙烯树脂，1～80重量份的乙烯共聚物树脂，及1～20份的聚乙烯、丙烯酸酯和马来酸酐的三元共聚物构成。本发明的组合物和包含它的汽车电缆减少有毒气体和烟的产生，是对生态环境友好的。另外，它们的物理性能如阻燃性、耐磨性、耐刮性、硬度和耐热性优异，并且能够高速挤出。
2	不含卤素的聚合物和利用它的汽车电线	CN200480035822.8	2004-02-27	CN1890316A	2007-01-03	金吾荣; 尹承勋; 林和俊
本发明公开一种用于不含卤素的汽车电缆的绝缘组合物，该绝缘组合物包含基质树脂，以及按100重量份的该基质树脂计为50～200重量份的金属氢氧化物阻燃剂和0.5～20重量份的抗氧剂，其中所述基质树脂由1～80重量份的聚乙烯树脂，1～80重量份的乙烯共聚物树脂，及1～20份的聚乙烯、丙烯酸酯和马来酸酐的三元共聚物构成。本发明的组合物和包含它的汽车电缆减少有毒气体和烟的产生，是对生态环境友好的。另外，它们的物理性能如阻燃性、耐磨性、耐刮性、硬度和耐热性优异，并且能够高速挤出。
3	人抗人白介素－18抗体及其片断和它们的利用方法	CN200480011618.2	2004-04-30	CN1780911A	2006-05-31	杉村和久; 中西宪司; 中岛敏博
本发明的源自人的人抗人IL－18抗体是对于人的IL－18的抗体，其含有由以下(a)或(b)的多肽组成的H链的互补性决定区，和由(c)或(d)的多肽组成的、对人白介素－18的L链的互补性决定区。(a)由序列号4～6所示的氨基酸序列组成的多肽。(b)在(a)中所述的多肽的异构体、成为H链的互补性决定区的多肽。(c)由序列号10～12所示的氨基酸序列组成的多肽。(d)在(c)中所述的多肽的异构体、成为L链的互补性决定区的多肽。由此，提供人抗人IL－18抗体以及其利用方法成为可能。
4	人抗人白介素－18抗体及其片断和它们的利用方法	CN200480011618.2	2004-04-30	CN100457901C	2009-02-04	杉村和久; 中西宪司; 中岛敏博
本发明的源自人的人抗人IL-18抗体是对于人的IL-18的抗体，其含有由以下(a)或(b)的多肽组成的H链的互补性决定区，和由(c)或(d)的多肽组成的、对人白介素-18的L链的互补性决定区。(a)由序列号4～6所示的氨基酸序列组成的多肽。(b)在(a)中所述的多肽的异构体、成为H链的互补性决定区的多肽。(c)由序列号10～12所示的氨基酸序列组成的多肽。(d)在(c)中所述的多肽的异构体、成为L链的互补性决定区的多肽。由此，提供人抗人IL-18抗体以及其利用方法成为可能。
5	(R/S)利福霉素衍生物，它们的制备和药物组合物	CN200580030859.6	2005-07-21	CN101031572B	2010-12-08	C·Z·丁; 马振坤; 李静; S·哈兰; 何勇; K·P·迈纳; I·H·金; J·C·朗古德; 靳亚非; K·D·康姆布林克
具有以下通式(I)结构的利福霉素衍生物(氢醌和相应的醌(C1-C4)形式)：或其盐、水合物或前药；其中优选的R1包含氢或乙酰基，优选的R2包含氢、甲基或其他低级烷基；其中星号(*)表示具有手性中心的碳，其中绝对构型是指定为R或S。还描述了制备前述的利福霉素衍生物的方法。该化合物表现出抗微生物活性，包括作用于耐药性微生物。流程图A：式I化合物的制备。
6	(R/S)利福霉素衍生物，它们的制备和药物组合物	CN200580030859.6	2005-07-21	CN101031572A	2007-09-05	C·Z·丁; 马振坤; 李静; S·哈兰; 何勇; K·P·迈纳; I·H·金; J·C·朗古德; 靳亚非; K·D·康姆布林克
具有以下通式(I)结构的利福霉素衍生物(氢醌和相应的醌(C1－C4)形式)：或其盐、水合物或前药；其中优选的R1包含氢或乙酰基，优选的R2包含氢、甲基或其他低级烷基；其中星号(*)表示具有手性中心的碳，其中绝对构型是指定为R或S。还描述了制备前述的利福霉素衍生物的方法。该化合物表现出抗微生物活性，包括作用于耐药性微生物。
7	3′-羟基苯并嗪并利福霉素衍生物的制备方法和含有它们的抗菌剂	CN89107160.1	1989-09-16	CN1042357A	1990-05-23	山根毅彦; 橋爪卓士; 山下胜治; 细江和典; 久世文幸; 渡边清
制备式(I)利福霉素衍生物或其药用盐，式中A为式的基团，其中R1为有4或5个碳原子的烷基，或为有3-5个碳原子的链烯基，或者为式的基团，其中n为3或4。该利福霉素衍生物(I)对于革兰氏阳性细菌和耐酸细菌具有显著的抗菌活性，并且对于结核杆菌也具有显著的抗菌活性。
8	包含3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)氨基衍生物的药物制剂以及它们的制备方法	CN201380053241.6	2013-08-09	CN104736152B	2018-01-23	R·G·康斯坦丁诺瓦; 基里尔·阿瑟诺夫·尼诺夫; 卫理士卡·里列瓦·阿波斯托洛娃-迪莫瓦; 伊夫提米亚·伊万诺瓦·斯戴凡诺瓦; 罗森·克鲁莫夫·科伊特切夫
本发明涉及制备包含作为活性物质的3‑甲酰基利福霉素SV和3‑甲酰基利福霉素S的3‑(4‑肉桂基‑1‑哌嗪基)‑氨基衍生物的药学上可接受的制剂的方法，所述药学上可接受的制剂具有针对革兰氏阳性和革兰氏阴性微生物以及针对结核分枝杆菌(tuberculous micobacteria)(包括非典型的和利福霉素抗性的)的高活性，并且涉及用于制备3‑甲酰基利福霉素SV和3‑甲酰基利福霉素S的3‑(4‑肉桂基‑1‑哌嗪基)‑氨基衍生物的方法。用于制备药物组合物的方法容易可行并且不需要用于其实施的特定设备。用于制备所述化合物的方法的特征是高收率和纯度，在物质的制备和分离中使用环境清洁的溶剂‑乙醇和水，以及在终产物中没有残留有机溶剂。
9	包含3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)氨基衍生物的药物制剂以及它们的制备方法	CN201380053241.6	2013-08-09	CN104736152A	2015-06-24	R·G·康斯坦丁诺瓦; 基里尔·阿瑟诺夫·尼诺夫; 卫理士卡·里列瓦·阿波斯托洛娃-迪莫瓦; 伊夫提米亚·伊万诺瓦·斯戴凡诺瓦; 罗森·克鲁莫夫·科伊特切夫
本发明涉及制备包含作为活性物质的3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)-氨基衍生物的药学上可接受的制剂的方法，所述药学上可接受的制剂具有针对革兰氏阳性和革兰氏阴性微生物以及针对结核分枝杆菌(tuberculous micobacteria)(包括非典型的和利福霉素抗性的)的高活性，并且涉及用于制备3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)-氨基衍生物的方法。用于制备药物组合物的方法容易可行并且不需要用于其实施的特定设备。用于制备所述化合物的方法的特征是高收率和纯度，在物质的制备和分离中使用环境清洁的溶剂-乙醇和水，以及在终产物中没有残留有机溶剂。
10	Thermoelectric materials and elements utilizing them	US46580654	1954-11-01	US2762857A	1956-09-11	LINDENBLAD NILS E

11	Thermoelectric materials and elements utilizing them	US60925556	1956-09-11	US2902529A	1959-09-01	BUSANOVICH CHARLES J

12	Pixel structure and display system utilizing the same	US13477674	2012-05-22	US08810559B2	2014-08-19	Du-Zen Peng; Tse-Yuan Chen; Chih-Chiang Tseng; Shou-Cheng Wang; Tsung-Yi Su
A pixel structure including a first switching transistor, a setting unit, a capacitor, a driving transistor, a second switching transistor and a luminous element is disclosed. The capacitor is coupled between a first and a second node. The first switching transistor transmits a data signal to the first node according to a scan signal. The driving transistor includes a threshold voltage and a gate coupled to the second node. The second switching transistor includes a gate receiving an emitting signal. The luminous element is coupled to the driving transistor and the second switching transistor in series between a first operation voltage and a second operation voltage. The setting unit controls the voltage levels of the first and the second nodes to compensate the threshold voltage of the driving transistor.
13	Pixel unit and display device utilizing the same	US12885519	2010-09-19	US08441599B2	2013-05-14	Chen-Pang Kung; Cheng-Chung Lee; Yu-Yang Chang; Chung-I Lee
A pixel unit including a first sub-pixel is disclosed. The first sub-pixel includes a first display medium, a second display medium, a first driving device, and a second driving device. The first driving device drives the first display medium. The second driving device drives the second display medium.
14	Pixel unit and display device utilizing the same	US11563718	2006-11-28	US07659956B2	2010-02-09	Yeong-Feng Wang; Chun-Hao Tung; Liang-Bin Yu
A pixel unit comprising a first metal layer and a second metal layer. The first metal layer comprises a gate electrode and a first electrode. The second metal layer comprises a drain electrode, a source electrode, and a second electrode. The drain electrode overlaps the gate electrode in a first overlapping region. The source electrode overlaps the gate electrode in a second overlapping region. The second electrode overlaps the first electrode in a third overlapping region. The size of the first electrode approximates that of the second electrode. The first electrode and the second electrode are staggered.
15	Zirconia ceramics and infrared ray radiation elements utilizing the same	US3585390D	1969-02-05	US3585390A	1971-06-15	ISHIKAWA TADASHI
Black zirconia ceramics are prepared by firing a mixture containing more than 45 percent, by weight, of a Zr02.Si02 component, up to 25 percent, by weight of a mineralizer consisting of manganese oxide, at least one of oxides of iron, cobalt, nickel or chromium, and the balance of clay. The fired black zirconia ceramics emit a large quantity of infrared rays of long wavelength when heated to about 500* C., and are suitable to effect, heating, baking, cooking, drying, etc.
16	Organometallic complex and organic el element by utilizing the same	JP2007036903	2007-02-16	JP2007224029A	2007-09-06	DAS RUPASREE RAGINI; KIM HEE-KYUNG; KWON O-HYUN; KIM MYEONG-SUK; TAMURA SHINICHIRO; PARK SHOSHIN; RYO GASHIN; RYU RIRETSU; BYUN YOUNG HUN
PROBLEM TO BE SOLVED: To provide an organometallic complex generating a high efficiency phosphorescence and an organic electric field light-emitting element by utilizing the same. SOLUTION: This organometallic complex is expressed by chemical formula: ML _mL' _n (chemical formula 1) [wherein, M is Ir, Os, Pt, Pb, Re, Ru or Pd; L and L' are different bidentate ligands; (m) is 1, 2 or 3; and (n) is (3-m)]. The organometallic complex is e.g. a compound having a structure of chemical formula 21, and used as a light-emitting layer-forming material of the organic electric field light-emitting element. COPYRIGHT: (C)2007,JPO&INPIT
17	利用選擇性細胞素(CYTOKINE)抑制藥物供治療及管控癌症及其它疾病之方法及組合物 METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES	TW092131072	2003-11-06	TW200501945A	2005-01-16	傑洛門B. 才迪斯 JEROME B. ZELDIS
本發明係揭示治療、預防及／或管控癌症，以及有關於或其特徵在於不想要的血管生成作用之疾病和病症的方法。該特定方法包括單獨或與第二個活性成分併用，投予選擇性細胞素抑制藥物。本發明進一步更關於降低或避免與化學療法、輻射療法、荷爾蒙療法、生物學療法或免疫療法有關之有害副作用的方法，其包括投予選擇性細胞素抑制藥物。亦揭示適用於本發明之方法的醫藥組合物、單一單位劑量形式和套組。
18	Antistatic composition and elements and processes utilizing same	US338401	1982-01-08	US4415626A	1983-11-15	Charles R. Hasenauer; Donald N. Miller
An antistatic composition useful to reduce the propensity of multilayer elements to accumulate static electrical charge comprises an aqueous dispersion of (a) a film-forming binder; (b) a hardener for the binder; (c) a substantially transparent matting agent having particles with a diameter in the range of from about 1 to about 50 microns and a specific gravity substantially the same as that of water; (d) a highly electrically conductive, noncrystallizable conductivity agent; and (e) a charge control agent. This antistatic composition is especially useful as an image-receiving layer on substantially transparent image-receiving elements. Such image-receiving elements can be formed into projection-viewable transparencies by an electrographic copy process, which transparencies are considerably less likely to stick to one another or jam in electrographic copier/duplicator equipment than currently available transparencies.
19	Rifamycin hydrazones, pharmaceutical compositions containing them and their use	US644886	1984-08-27	US4551450A	1985-11-05	Peter Traxler
Novel hydrazones derived from 3-formylrifamycin S or SV as the aldehydo component and a bi- or tri-cyclic N-aminopiperazine as the hydrazino component and having the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6, independently of one another, each represents a hydrogen atom or C.sub.1-4 -alkyl,m and n, independently of one another, each represents an integer from 0 to 5,X represents C.sub.1-5 -alkylidene, benzylidene or C.sub.1-4 -alkoxymethylene,Y represents C.sub.1-5 -alkylidene, C.sub.1-4 -alkoxymethylene, oxy, thio or optionally substituted imino of the formula --N(R)-- wherein R represents hydrogen, C.sub.1-4 -alkyl, C.sub.3-5 -alkenyl, C.sub.3-12 -cycloalkyl or phenyl, orX and Y together represent 1,2-cycloalkylene or o-phenylene each of which can be substituted by from one to three C.sub.1-4 -alkyl radicals, andRif represents a radical of rifamycin S or SV that is bonded in the 3-position by the free valency,are distinguished by a high and long-lasting antituberculotic activity. They are manufactured in conventional manner, for example by condensation of their components.
20	Analogs of calicheamicin gamma1I, method of making and using the same	US915071	1992-07-16	US5264586A	1993-11-23	Kyriacos C. Nicolaou; Adrian L. Smith; Chan-Kou Hwang; Emmanuel Pitsinos
Chimeric analogs of calicheamicin that include an analog of calicheamicinone linked to an ester or glycoside, (-)-calicheamicinone and its analogs are disclosed.

1 2 3 4 5 6 7 8 9 10

IPRDB

热门服务

关于我们

友情链接

联系方式